Review



correlation coefficients (r)  (Wolters Kluwer Health)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Wolters Kluwer Health correlation coefficients (r)
    Correlation Coefficients (R), supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/pearson+correlation+coefficient/10__1097_slash_ncc__0000000000001469-80-5-16
    Average 90 stars, based on 1 article reviews
    correlation coefficients (r) - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Measuring Self-care in Patients With Hypertension
    Article Snippet: High blood pressure (HBP) is a leading contributor to the global burden of disease, affecting more than 1 in every 4 US adults (965 million people) and generating approximately $13 billion in direct healthcare cost annually.. Self-care is defined as ‘‘actions directed toward oneself or the environment in order to regulate one’s functioning in the interest of one’s life, integrated functioning, and well-being.’’ Cumulative evidence suggests that HBP self-care is crucial for blood pressure (BP) control and for preventing complications such as stroke and early death.. The critical domains of HBP self-care include medication taking and various lifestyle factors such as a low-sodium and low-fat diet, exercise, restricting alcohol consumption, nonsmoking, weight management, self-monitoring of BP, regular doctor visit, and stress reduction.

    Article Title: Reliability of the Pedar in-shoe system for plantar pressure measurement in diabetic patients with and without neuropathy
    Article Snippet: Background: The aim of this study was to evaluate within and between days’ reliability of the Pedar in-shoe system (Novel GmbH, Munich, Germany) to measure plantar pressure in diabetic patients with and without neuropathy.

    Article Title: The Effect of Women’s Perceptions of Their Nurses’ Communication on Their Distress and Fear of Cancer During Colposcopy
    Article Snippet: Background: Effective communication between nurses and women can help determine women’s stress and fear levels during colposcopy and enable appropriate interventions to be taken.. Objective: This study aimed to examine the effect of women’s perceptions of nurse communication on their levels of distress and cancer worry during colposcopy.. Methods:This descriptive and correlational studywas conducted with 227 women who underwent colposcopy at three hospitals between December 2023 and May 2024.



    Similar Products

    pearson's correlation coefficient (r) test  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson's correlation coefficient (r) test
    Pearson's Correlation Coefficient (R) Test, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/correlation+coefficient/us12306192-518-11-18
    Average 90 stars, based on 1 article reviews
    pearson's correlation coefficient (r) test - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    correlation coefficient (r)  (GraphPad Software Inc)
    90
    GraphPad Software Inc correlation coefficient (r)
    Correlation Coefficient (R), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/correlation+coefficient/pm40343905-177-1-7
    Average 90 stars, based on 1 article reviews
    correlation coefficient (r) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson’s correlation coefficient(r) calculated in graphpad prism  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson’s correlation coefficient(r) calculated in graphpad prism
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient(r) Calculated In Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/correlation+coefficient/pmc12064836-34-6-11
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient(r) calculated in graphpad prism - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    squared pearson correlation coefficient (r 2)  (GraphPad Software Inc)
    90
    GraphPad Software Inc squared pearson correlation coefficient (r 2)
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Squared Pearson Correlation Coefficient (R 2), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/pearson+correlation+coefficient/pmc12028599-196-6-13
    Average 90 stars, based on 1 article reviews
    squared pearson correlation coefficient (r 2) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r) using r studio  (RStudio)
    90
    RStudio pearson correlation coefficient (r) using r studio
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R) Using R Studio, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/pearson+correlation/pm40114072-189-0-5
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r) using r studio - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient r  (DuPont de Nemours)
    90
    DuPont de Nemours pearson correlation coefficient r
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient R, supplied by DuPont de Nemours, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/pearson+correlation+analysis/10__1080_slash_15320383__2025__2467237-65-6-24
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient r - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    correlation coefficients (r)  (Wolters Kluwer Health)
    90
    Wolters Kluwer Health correlation coefficients (r)
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Correlation Coefficients (R), supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/pearson+correlation+coefficient/10__1097_slash_ncc__0000000000001469-80-5-16
    Average 90 stars, based on 1 article reviews
    correlation coefficients (r) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r) with  (MathWorks Inc)
    90
    MathWorks Inc pearson correlation coefficient (r) with
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R) With, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/pmc11817788-331-11-16
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r) with - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson’s correlation coefficient (r)  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson’s correlation coefficient (r)
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient (R), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/correlation+coefficients+(r)/pearson+correlation+coefficient/pmc11684645-76-7-32
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient (r) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

    doi: 10.1038/s41467-025-59588-3

    Figure Lengend Snippet: a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Article Snippet: The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies.

    Techniques: Comparison, Clinical Proteomics, Two Tailed Test